Announcements Trials
Browse Landscape

Phase

Phase 1 25Phase 2 16Phase 1/2 14Phase 3 2Phase EARLY_PHASE1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Patient Preference 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 361Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × decitabine and cedazuridine drug combination × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡